U.S. regulators have approved a label expansion for Novo Nordisk’s obesity drug Wegovy, highlighting its benefits for the heart. This move is expected to increase demand and insurance coverage for the popular treatment. The new label indicates that Wegovy can help reduce the risk of major heart complications for individuals with overweight or obesity and existing heart disease. This decision was based on a five-year trial showing a 20% reduction in cardiovascular problems with the use of Wegovy. This makes Wegovy the first weight loss treatment approved to improve heart outcomes as well.
Source link
Novo Nordisk gets FDA approval to tout heart benefits of Wegovy
